New York, February 11, 2015 -- Moody's Investors Service commented that Envision Pharmaceutical Holdings, Inc.'s ("Envision's") ratings (B3 CFR) and stable outlook remain unchanged following news that Rite Aid Corporation (B2 CFR ratings on review for downgrade) plans to acquire Envision for approximately $2 billion, of which $1.8 billion will be funded with incremental debt. For further information, please see Moody's Issuer Comment on Envision on www.moodys.com.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.